New hope for tough nasopharyngeal cancer: Triple-Drug combo trial launches
NCT ID NCT07581821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) in 33 adults with recurrent or metastatic nasopharyngeal cancer that has not responded to prior immunotherapy. The goal is to see if this combo can shrink tumors or control the disease. Participants must be 18-65 and have failed at least one prior standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pembrolizumab & Olaparib for Nasopharyngeal Canc NCT04825990
- AK112 & AK117 Combo for Advanced Tumors (NCT05229497)
- MRG003 for Recurrent Nasopharyngeal Cancer – NCT05126719
- Combination Therapy for Nasopharyngeal Cancer (NCT05807880)
- MRG003 + Pucotenlimab for NPC Trial (NCT06976190)
- YL201 + Toripalimab for Nasopharyngeal Cancer NCT07258979
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai, Guangdong, China, 519000
RECRUITINGZhuhai, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••